US FDA reviewer backs one lixivaptan use, but not other
This article was originally published in Scrip
Executive Summary
Shares of Cornerstone Therapeutics rose as high as 7% on 11 September after a US FDA drug reviewer said an argument could be made for approval of lixivaptan, an orally-active, selective vasopressin 2 receptor antagonist, as a treatment for hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion, or SIADH, based on the currently available information, as long as the therapy is restricted to inpatient initiation.